Geron appoints John Scarlett as new CEO
Scarlett has an experience of over 25 years in the pharmaceutical and biotechnology industry. Previously, he served as President and Chief Executive Officer of Proteolix, a biotechnology company
HAYA Therapeutics has secured fast track designation from the US Food and Drug Administration (FDA) for its investigational therapy, HTX-001, to treat symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
Regional distributors join InVitria’s worldwide distributors including Sigma-Aldrich and Thermo Fisher Scientific. The company’s distribution network will provide regional distribution options for customers in North America, Europe, Asia,